[Surgical procedures in patients treated with platelet function inhibitors].
The platelet function inhibitors (PFI) acetylsalicylic acid (ASA) and clopidogrel are widely used in a broad spectrum of atherothrombotic diseases, either as mono- or dual antiplatelet therapy. Platelet function is inhibited for the whole lifespan of platelets (10 days). In case of surgical procedures the bleeding risk under continued antiplatelet therapy has to be balanced against the risk of ischemic complications due to withdrawal of antiplatelet therapy. Especially after stent implantation, the high risk and unfavorable prognosis of stent thrombosis have to be considered. Whereas surgical procedures with a low bleeding risk may be performed with continued antiplatelet therapy, there is a need for partial or total discontinuation of antiplatelet therapy in surgical procedures with higher bleeding risks.
Rupprecht
Hans-Jürgen
HJ
Medizinische Klinik, Klinikum Rüsselsheim, Rüsselsheim. hj.rupprecht@gp-ruesselsheim.de
Blank
Ralf
R
Konradi
Dorothee
D
Andreas
Klaus
K
Auerbach
Holger
H
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000295:instrumentation; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006470:Hemorrhage / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D010818:Practice Patterns, Physicians' / Q000639:trends; D015607:Stents / Q000009:adverse effects; D013514:Surgical Procedures, Operative / Q000379:methods*; D013927:Thrombosis / Q000188:drug therapy*
D010975:Platelet Aggregation Inhibitors